For U.S. biotech & life-science companies · Phase 2 onwards
Your trial moves while New York sleeps.
Antipode Clinical takes U.S. drug candidates that have finished Phase 1 into Phase 2 and later clinical trials in Australia. We set up the local sponsor, clear ethics and the TGA notification, pick and manage the sites, structure the R&D rebate, and can co-fund the Australian portion. The data is generated to ICH-GCP so it can support your FDA filings.
A Berkshire AI, Inc. company · Delaware, USA
Send a question at the end of your day and the Sydney team has a working day to answer it before you're back at your desk.
Why Australia
Faster to first patient. Cheaper once the rebate lands.
Australia runs Phase 2 and later trials under the same TGA Clinical Trial Notification scheme it uses for first-in-human work. Ethics approval comes first, then the sponsor notifies the TGA, and the government refunds a large share of eligible spend.
Typical time from ethics submission to a study ready to start under the CTN scheme.[1]
Refundable R&D tax offset on eligible Australian spend, for groups with turnover under A$20M.[2]
Australian Phase 2 data, run to ICH-GCP, can support your End-of-Phase 2 meeting and U.S. filings. No U.S. IND is required to run the Australian study itself.[3]
Lower net cost than an equivalent U.S. early-phase study once the rebate is applied, per industry estimates. Your figure depends on design and sites.[4]
The pathway
From your data room to a dosed patient.
The steps below run in order. Timing is indicative and assumes a program with completed Phase 1 safety and PK data and drug supply ready for a Phase 2 study.
Program review
We read your mechanism, Phase 1 results, CMC status and target indication, and tell you plainly whether Australia fits the program and what it will cost.New York
Australian sponsor
A CTN has to be lodged by an Australian sponsor. We incorporate and run a local subsidiary for you, or act as local sponsor, and register it for the R&D Tax Incentive.Sydney
Sites, CRO and protocol
We shortlist sites and CROs for your indication, negotiate budgets, and adapt the protocol and investigator brochure for Australian ethics review.Sydney
HREC approval and CTN
A Human Research Ethics Committee reviews and approves the study. The sponsor then notifies the TGA, and the site can open.Sydney
Oversight on your behalf
We sit on the sponsor side: tracking enrolment, spend and data quality against plan, with a weekly report timed for your Monday morning.Sydney → New York
Rebate and FDA bridge
We prepare the R&D Tax Incentive claim after the Australian financial year closes, and assemble the clinical package for your End-of-Phase 2 meeting and Phase 3 planning.New York + Sydney
What we do
An operator and a co-funder in one engagement.
Antipode combines two things we already do in Australia: sponsoring our own clinical program, and co-funding trials for listed biotechs. You can use either side on its own.
Run the Australian trial
- Local sponsor entity, company secretary and R&D registration
- Site and CRO selection, budgets and contracts
- Ethics submissions and the TGA Clinical Trial Notification
- Sponsor oversight through last patient out
- ICH-GCP data package for FDA use, including End-of-Phase 2 meeting preparation
Close the cash gap
- The rebate is paid after the financial year closes, often many months after the spend
- Where a program passes our diligence, we co-fund the Australian portion against its expected rebate
- Terms are set per program and tied to named clinical milestones
- No platform fees on programs we do not fund
Rebate estimate
What the R&D Tax Incentive could return.
Enter the spend you expect to incur in Australia. The figures show the arithmetic only. Whether each dollar is eligible depends on the activity, the entity and the registration.
Paid as cash after the Australian financial year ends on 30 June and the claim is lodged. Larger groups receive a non-refundable offset instead, which reduces tax payable rather than paying cash.
Who this is for
Programs that gain the most from starting here.
Assets with a clean Phase 1
Small molecules and biologics moving into Phase 2a proof-of-concept or Phase 2b dose-ranging, where a faster start brings the efficacy readout forward.
Repurposed and well-characterised drugs
Phase 2 proof-of-concept on a known molecule in a new indication, where speed and cost decide whether the study happens at all.
Venture-backed teams watching runway
Seed to Series B companies that need a clinical readout before the next raise and can't fund a U.S.-priced study.
Founder
Dave Parmar
Founder & CEO · New York
I've sponsored a trial in Australia and co-funded others. Antipode packages what we learned for U.S. companies that haven't done it before.
- Training
- Bachelor of Science in Pharmacology, University of Otago, New Zealand.
- Aurelix Bio
- Founder of a Sydney clinical-stage company sponsoring a Phase 2b program of a repurposed small molecule in Australia.
- Point8 Capital
- Founder of a Sydney investment firm providing clinical trial co-funding facilities to ASX-listed biotech companies.
- RoseRx
- Co-founder of RoseRx (formerly Rosemary Health), a conversational AI platform for pharma HCP and patient engagement, backed by Breyer Capital.
Send your program
Tell us about the molecule. We'll tell you if Australia fits.
A two-page summary is enough for a first read. Please include:
- Mechanism of action and target indication
- Phase 1 safety, tolerability and PK results
- CMC and drug supply status
- Proposed first study and its main endpoint
- Cash runway and the readout you need before your next raise
We reply within five business days. We'll sign your mutual NDA before you share anything confidential.